Boehringer Ingelheim announces results from phase 2 trial for liver disease treatment

Betsy Goodfellow | February 26, 2024 | News story | Research and Development |  Boehringer Ingelheim, Hepatology, clinical trial, liver disease, survodutide 

Boehringer Ingelheim has announced results from the phase 2 trial of survodutide for the treatment of liver disease due to metabolic dysfunction-associated steatohepatitis (MASH).

The trial demonstrated that 83% of adults treated with the drug achieved a statistically significant improvement of MASH compared to placebo (18.2%). The trial met its primary endpoint of reaching a biopsy-proven improvement in MASH after 48 weeks, without the worsening of fibrosis stages F1, F2 and F3 (mild to moderate or advanced scarring).

The drug also met all of its secondary endpoints, such as a statistically significant improvement in liver fibrosis.

It is expected that full data will be presented in the next few months.

Dr Arun Sanyal MD professor of medicine, physiology and molecular pathology at Virginia Commonwealth University School of Medicine, US, and principal investigator on the trial, commented: “I am thrilled to see these statistically significant results from the phase 2 trial of survodutide in MASH and fibrosis. These data position survodutide as a potential leading treatment for a population with great unmet medical needs, and will bring hope to people living with MASH and with fibrosis. I am looking forward to sharing further detail on key secondary endpoints, including the percentage of adults who saw an improvement in fibrosis, at a congress in the first half of this year.”

Betsy Goodfellow